## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average b	ourden
hours per response:	0.5

to Section 16	ox if no longer subject . Form 4 or Form 5 ay continue. <i>See</i> b).		Filed pursu	ant to Section 16(a	) of the Securi	ies Exchange A	Act of 1934	ERSH	HP	Estima	Number: ated average bu per response:		87 0.5
1. Name and Add Hudson Th	dress of Reporting omas J	Person*				(Check	all applicable Director Officer (give	,		10% Owner Other (specify			
(Last) (First) (Middle) 1 NORTH WAUKEGAN ROAD		( )	e) 3. Date of Earliest Transaction (Month/Day/Year) 02/25/2022						,	below) SVP, R&D and		below) CSO	
(Street) NORTH CHICAGO	AUKEGAN ROAD AUKEGAN ROAD   IL 60064   4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)   X Form filed by One Reporting Person Form filed by More than One Reporting		le										
(City)	(State)	(Zip)	AbbVie Inc. [ ABBV ] (Check all applicable Director X Officer (give below) 3. Date of Earliest Transaction (Month/Day/Year) 02/25/2022 4. If Amendment, Date of Original Filed (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) Compared to the securities Acquired, Disposed of, or Beneficially Owned										
		Table I - Non-De	rivative	Securities Ac	quired, Dis	posed of, o	or Benefi	icially	Owned				
4 Title - ( 0									F A		a ann an bin	7. 1.	

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock, \$0.01 par value	02/25/2022		F		13,408	D	\$149.54	46,228	D	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

## Steven L. Scrogham, attorney-

03/01/2022 in-fact for Thomas J. Hudson

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.